Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pancreatic Neoplasms × Octreotide × Clear all

Phase

Phase NA 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 4 Colorectal Neoplasms 4 Rectal Neoplasms 3 Diarrhea 3 Gastro-enteropancreatic neuroendocrine tumor 2 Colonic Neoplasms 2 Carcinoma, Hepatocellular 2 Carcinoid Tumor 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Malignant Carcinoid Syndrome 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Drug-Related Side Effects and Adverse Reactions 1 Carcinoma 1 Breast Neoplasms 1 Anus Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Gemcitabine 68 Fluorouracil 28 Oxaliplatin 18 Leucovorin 18 Capecitabine 13 130-nm albumin-bound paclitaxel 12 Irinotecan 9 Albumin-Bound Paclitaxel 9 irinotecan sucrosofate 7 Radiotherapy 6 Taxes 5 Erlotinib Hydrochloride 5 folfirinox 4 rubitecan 3 Surgical Procedures, Operative 3 Specimen Handling 3 Pancreaticojejunostomy 3 Neoadjuvant Therapy 3 Drug Therapy 3 Cisplatin 3 ruxolitinib 2 masitinib 2 dehydroftorafur 2 Saline Solution 2 S 1 (combination) 2 Paclitaxel 2 GV1001 peptide 2 Fentanyl 2 Chemotherapy, Adjuvant 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02457156 2025-03-13

PANasta

University of Liverpool

Phase 3 Completed

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡